Immune Checkpoint Inhibitors [inhibitory kontrolních bodů]
- Terms
-
blokáda imunitních kontrolních bodů
blokáda kontrolních bodů imunitní reakce
blokáda PD-1/PD-L1
blokátory kontrolních bodů imunitní reakce
check-point inhibitory
checkpoint inhibitory
CTLA4 inhibitor
CTLA4 inhibitory
inhibice kontrolních bodů imunitní reakce
inhibitor kontrolních bodů imunitní reakce
inhibitor PD-1
inhibitor PD-L1
inhibitory kontrolního bodu imunitní reakce
inhibitory PD-1
inhibitory PD-L1
-
CTLA-4 Inhibitor
CTLA-4 Inhibitors
Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor
Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors
Immune Checkpoint Blockade
Immune Checkpoint Blockers
Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor
PD-1 Inhibitor
PD-1 Inhibitors
PD-1-PD-L1 Blockade
PD-L1 Inhibitor
PD-L1 Inhibitors
Programmed Cell Death Protein 1 Inhibitor
Programmed Cell Death Protein 1 Inhibitors
Programmed Death-Ligand 1 Inhibitors
Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies.
- DUI
- D000082082 MeSH Browser
- CUI
- M000675754
- Previous indexing
- Antineoplastic Agents (2017-2020)
- History note
- 2021
- Public note
- 2021
Allowable subheadings
- AD
- administration & dosage 55
- AE
- adverse effects 76
- AN
- analysis 4
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry 2
- CL
- classification 20
- EC
- economics 4
- HI
- history
- IM
- immunology 7
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics 2
- PD
- pharmacology 109
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 274
- TO
- toxicity
- UR
- urine